Daily dietary supplement containing:

  • With added vegetable sterols
  • Resveratrol
Om3gafortSCC uses HIGH CONCENTRATION omega-3 polyunsaturated fatty acids EPA/DHA, EFFICACY, PURITY and SAFETY obtained with an ENVIRONMENTALLY FRIENDLY technology known as Supercritical Concentration (SCC).

Omegafort cholesterol, a winning combination



Daily dose: 2 capsules. % DV based on daily dose.

2 capsules % DV*
Omega-3 fatty acids# 1045 mg **
EPA (eicosapentaenoic acid) 799 mg **
DHA (docosahexaenoic acid) 123 mg **
Other omega-3 123 mg **
Other active ingredients
Plant sterols 701,1 mg **
Vitamin E 12 mg 100%
Resveratrol 10,2 mg **
Vitamin A 800 µg 100%

*Recommended daily amount as per Directive 2008/100/CE of 28 October 2008.
**Daily value not established.
#Guaranteed minimum quantity of the active ingredient expressed in mg. Percentages calculated on the basis of the minimum quantity expressed in mg are subject to variation.


Fish Oil (minimum: 65% EPA [eicosapentaenoic acid] and 10% DHA [docosahexaenoic acid] and other omega-3), 21,7 g/100 g plant sterols, gelatin, glycerin, emulsifier: glyceryl monostearate, medium chain triglycerides, thickener: soya lecithin, vitamin E (D-alpha-tocopheryl acetate), resveratrol, antioxidants: tocopherol-rich extract , vitamin A (retinyl palmitate), color additives (E171 and E129).

Greater concentration, greater efficacy

  1. Saito Y, Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K; JELIS Investigators, Japan. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis. 2008 Sep;200(1):135-40. Epub 2008 Jun 19.
  1. Jan L Breslow. Supplement: n–3 Fatty Acids: Recommendations for Therapeutics and Prevention n–3 Fatty acids and cardiovascular disease. American Journal of Clinical Nutrition, Vol. 83, No. 6, S1477-1482S, June 2006 
  2. Abeywardena MY, Head RJ. Longchain n-3 polyunsaturated fatty acids and blood vessel function. Cardiovasc Res. 2001 Dec;52(3):361-71.
  3. Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol. 2011 Nov 8;58(20):2047-67.
  1. Khandelwal S, Demonty I, Jeemon P, Lakshmy R, Mukherjee R, Gupta R, Snehi U, Niveditha D, Singh Y, van der Knaap HC, Passi SJ, Prabhakaran D, Reddy KS. Independent and interactive effects of plant sterols and fish oil n-3 long-chain polyunsaturated fatty acids on the plasma lipid profile of mildly hyperlipidaemic Indian adults. Br J Nutr. 2009 Sep;102(5):722-32.
  2. Lewis SJ. Prevention and treatment of atherosclerosis: a practitioner’s guide for 2008. Am J Med. 2009 Jan;122(1 Suppl):S38-50.
  3. AbuMweis SS, Jones PJ. Cholesterol-lowering effect of plant sterols. Curr Atheroscler Rep. 2008 Dec;10(6):467-72.
  1. Jenkins DJ, Kendall CW, Nguyen TH, Marchie A, Faulkner DA, Ireland C, Josse AR, Vidgen E, Trautwein EA, Lapsley KG, Holmes C, Josse RG, Leiter LA, Connelly PW, Singer W. Effect of plant sterols in combination with other cholesterol-lowering foods. Metabolism. 2008 Jan;57(1):130-9.
  2. Earnest CP, Mikus CR, Lemieux I, Arsenault BJ, Church TS. Examination of encapsulated phytosterol ester supplementation on lipid indices associated with cardiovascular disease. Nutrition. 2007 Sep;23(9):625-33. Epub 2007 Jul 20.
  3. Ortega RM, Palencia A, López-Sobaler AM. Improvement of cholesterol levels and reduction of cardiovascular risk via the consumption of phytosterols. Br J Nutr. 2006 Aug;96 Suppl 1:S89-93.
  1. Leifert WR, Abeywardena MY. Cardioprotective actions of grape polyphenols. Nutr Res. 2008 Nov;28(11):729-37. 
  2. Dohadwala MM, Vita JA. Grapes and cardiovascular disease. J Nutr. 2009 Sep;139(9):1788S-93S. Epub 2009 Jul 22.